เกี่ยวกับตอนนี้
Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2022.11.14.516419v1?rss=1
Authors: Sankaranarayanan, I., Tavares-Ferreira, D., Mwrigi, J. M., Mejia, G. L., Burton, M. D., Price, T. J.
Abstract:
Chemotherapy-induced peripheral neuropathy (CIPN) is a primary dose-limiting side effect caused by antineoplastic agents, such as paclitaxel. This causes damage to peripheral nerves and the dorsal root ganglia (DRG). Currently, there are no effective treatments for CIPN, which can lead to long-term morbidity in cancer patients and survivors. Neuro-immune interactions occur in CIPN and have been implicated both in the development and progression of the disease and disease resolution. We investigated the potential role of Inducible co-stimulatory molecule (ICOS) in the resolution of CIPN pain-like behaviors in mice. ICOS is an immune checkpoint molecule that is expressed on the surface of activated T cells and promotes proliferation and differentiation of T cells. We found that intrathecal administration of ICOS agonist antibody (ICOSaa) alleviates mechanical hypersensitivity caused by paclitaxel and facilitates the resolution of mechanical sensitivity in female mice. Administration of ICOSaa reduced astrocyte-gliosis in the spinal cord and satellite cell gliosis in the DRG of mice previously treated with paclitaxel. Mechanistically, ICOSaa intrathecal treatment promoted pain resolution by increasing interleukin 10 (IL-10) expression in the dorsal root ganglion. In line with these observations, blocking IL-10 receptor (IL-10R) activity occluded the effects of ICOSaa treatment on CIPN behavior in female mice. Suggesting a broader activity in neuropathic pain, ICOSaa also partially resolved mechanical hypersensitivity in the spared nerve injury (SNI) model. Our findings support a model wherein ICOSaa administration induces IL-10 expression to facilitate neuropathic pain relief in female mice. ICOSaa treatment is in clinical development for solid tumors and given our observation of T cells in the human DRG, ICOSaa therapy could be developed for combination chemotherapy - CIPN clinical trials.
Copy rights belong to original authors. Visit the link for more info
Podcast created by Paper Player, LLC
http://biorxiv.org/cgi/content/short/2022.11.14.516419v1?rss=1
Authors: Sankaranarayanan, I., Tavares-Ferreira, D., Mwrigi, J. M., Mejia, G. L., Burton, M. D., Price, T. J.
Abstract:
Chemotherapy-induced peripheral neuropathy (CIPN) is a primary dose-limiting side effect caused by antineoplastic agents, such as paclitaxel. This causes damage to peripheral nerves and the dorsal root ganglia (DRG). Currently, there are no effective treatments for CIPN, which can lead to long-term morbidity in cancer patients and survivors. Neuro-immune interactions occur in CIPN and have been implicated both in the development and progression of the disease and disease resolution. We investigated the potential role of Inducible co-stimulatory molecule (ICOS) in the resolution of CIPN pain-like behaviors in mice. ICOS is an immune checkpoint molecule that is expressed on the surface of activated T cells and promotes proliferation and differentiation of T cells. We found that intrathecal administration of ICOS agonist antibody (ICOSaa) alleviates mechanical hypersensitivity caused by paclitaxel and facilitates the resolution of mechanical sensitivity in female mice. Administration of ICOSaa reduced astrocyte-gliosis in the spinal cord and satellite cell gliosis in the DRG of mice previously treated with paclitaxel. Mechanistically, ICOSaa intrathecal treatment promoted pain resolution by increasing interleukin 10 (IL-10) expression in the dorsal root ganglion. In line with these observations, blocking IL-10 receptor (IL-10R) activity occluded the effects of ICOSaa treatment on CIPN behavior in female mice. Suggesting a broader activity in neuropathic pain, ICOSaa also partially resolved mechanical hypersensitivity in the spared nerve injury (SNI) model. Our findings support a model wherein ICOSaa administration induces IL-10 expression to facilitate neuropathic pain relief in female mice. ICOSaa treatment is in clinical development for solid tumors and given our observation of T cells in the human DRG, ICOSaa therapy could be developed for combination chemotherapy - CIPN clinical trials.
Copy rights belong to original authors. Visit the link for more info
Podcast created by Paper Player, LLC
ภาษาอังกฤษ
สหรัฐอเมริกา
ค้นหาตอนที่ผ่านมา
ค้นหาตอนที่ผ่านมาของ PaperPlayer biorxiv neuroscience
ตอนอื่นๆ ใน PODCAST นี้
Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2022.12.30.522096v1?rss=1
Authors: Whitmarsh, S., Nguyen-Michel, V.-H., Lehongre, K., Mathon, B., Adam, C., Lambrecq, V. L., Frazzini, V., Navarro, V.
Abstract:
Epileptic seizures and interictal epileptiform discharges (IEDs) are stron…
Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2022.12.30.522216v1?rss=1
Authors: Regev, T. I., Casto, C., Hosseini, E. A., Adamek, M., Brunner, P., Fedorenko, E.
Abstract:
A left-lateralized network of frontal and temporal brain regions is specialized for language processing-spoke…
Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2022.12.30.522289v1?rss=1
Authors: Zhao, Z., Liu, Z., Chen, L., Chen, W., Guo, H., Wang, J., Mai, Y., Wei, X., Ding, J., Ge, F., Fan, Y., Guan, X.
Abstract:
Adolescent cocaine exposure (ACE) induce anxiety and higher sensitivity to dru…
Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2022.12.28.522095v1?rss=1
Authors: Melo, M. R., Wykes, A. D., Connelly, A. A., Bassi, J. K., Cheung, S. D., McDougall, S. J., Menuet, C., Bathgate, R. A., Allen, A. M.
Abstract:
The preBotzinger Complex (preBotC), a key primary generat…
Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2022.12.29.522264v1?rss=1
Authors: Kleinfeld, D., Liao, S.-M.
Abstract:
The breathing rhythm serves as a reference that paces orofacial motor actions and orchestrates active sensing. Past work reports that pacing occurs solely at a fix…
ข้อสงวนสิทธิ์: พอดแคสต์และอาร์ตเวิร์คที่ฝังอยู่ในหน้านี้มาจาก PaperPlayer ซึ่งเป็นทรัพย์สินของเจ้าของและไม่มีส่วนเกี่ยวข้องหรือรับรองโดย Listen Notes, Inc.